Cerebrospinal Fluid Proteome Analysis in Alzheimer's Disease

Encompassing mass spectrometry proteomic data from cerebrospinal fluid samples of Alzheimer's disease patients and non-demented controls. It was generated by Payam Emami Khoonsari in 2020 using label-free shotgun mass spectrometry and processed with five analysis programs. The study identified eight proteins with significantly lower levels in Alzheimer's disease patients.

Use Cases

• Compare protein quantification results from five analysis programs (DecyderMS, Maxquant, OpenMS, PEAKS, Sieve) to assess reproducibility and identification performance.
• Identify potential biomarkers for Alzheimer's disease by analyzing differential protein levels, such as the eight verified proteins (A2GL, APOM, C1QB, C1QC, C1S, FBLN3, PTPRZ, SEZ6).
• Evaluate normalization methods for cerebrospinal fluid proteomics, comparing global normalization to spiked-in chicken ovalbumin normalization.
• Investigate the biological roles of identified proteins, which span cell adhesion, migration, synapse regulation, and immune system function.

Strengths

• Data processed and compared using five distinct mass spectrometry analysis programs (DecyderMS, Maxquant, OpenMS, PEAKS, Sieve).
• Includes verification of eight specific proteins with significantly altered levels in Alzheimer's disease patients.
• Study evaluates three different normalization methods for proteomic data analysis.

Limitations

• Sample size and number of rows are not specified in the provided input.
• The dataset is from a single study, which may limit generalizability.
• Specific column structure and raw data file formats are unknown.

Provenance

Source

Dryad

Collection Method

Label-free shotgun mass spectrometry analysis of cerebrospinal fluid proteome.

Freshness

Last updated in 2020.